Luminita Schneider
YOU?
Author Swipe
View article: Evolution of Antiretroviral Strategies and Costs Over 2015-2022: The Real-Life Experience of an HIV Clinic in Paris, France
Evolution of Antiretroviral Strategies and Costs Over 2015-2022: The Real-Life Experience of an HIV Clinic in Paris, France Open
View article: Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir
Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir Open
Background In the NEAT022 trial, switching from boosted PIs (PI/r) to dolutegravir in people with HIV (PWH) with high cardiovascular risk decreased plasma lipids, soluble CD14 and adiponectin, and showed consistent favourable, although non…
View article: High uptake of vaccination against mpox in men who have sex with men (MSM) on HIV pre-exposure prophylaxis (PrEP) in Paris, France
High uptake of vaccination against mpox in men who have sex with men (MSM) on HIV pre-exposure prophylaxis (PrEP) in Paris, France Open
View article: Sexually Transmitted <i>Trichophyton mentagrophytes</i> Genotype VII Infection among Men Who Have Sex with Men
Sexually Transmitted <i>Trichophyton mentagrophytes</i> Genotype VII Infection among Men Who Have Sex with Men Open
Transmission of dermatophytes, especially Trichophyton mentagrophytes genotype VII, during sexual intercourse has been recently reported. We report 13 such cases in France. All patients were male; 12 were men who have sex with men. Our fin…
View article: Hepatitis A, hepatitis B and HPV vaccine needs and coverage in MSM initiating HIV PrEP in a sexual health clinic in Paris
Hepatitis A, hepatitis B and HPV vaccine needs and coverage in MSM initiating HIV PrEP in a sexual health clinic in Paris Open
International audience
View article: Intermittent Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment Maintains High Level of Viral Suppression in Virally Suppressed People Living with HIV
Intermittent Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment Maintains High Level of Viral Suppression in Virally Suppressed People Living with HIV Open
In this observational study, we aimed to evaluate whether bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) administered 5 or 4 days a week is able to maintain viral suppression in people living with HIV (PLHIV). We enrolled 85 pat…
View article: Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial
Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial Open
Background In the NEAT022 trial, virologically suppressed persons with human immunodeficiency virus (HIV) at high cardiovascular risk switching from protease inhibitors to dolutegravir either immediately (DTG-I) or after 48 weeks (DTG-D) s…
View article: Birth Country Influences the Choice of Antiretroviral Therapy in HIV-Infected Individuals: Experience From a French HIV Centre
Birth Country Influences the Choice of Antiretroviral Therapy in HIV-Infected Individuals: Experience From a French HIV Centre Open
Objectives: To assess whether antiretroviral therapy (ART) prescriptions differ between naive and virally suppressed HIV patients born in France (PBFs) and in Sub-Saharan Africa (PBSSAs). Setting: Observational single-center study. Methods…
View article: Integrating Human Immunodeficiency Virus–Specific Elements in the Treatment of Tobacco Dependence (ANRS 144 Inter-ACTIV)
Integrating Human Immunodeficiency Virus–Specific Elements in the Treatment of Tobacco Dependence (ANRS 144 Inter-ACTIV) Open
International audience
View article: Raltegravir 1200 mg once daily as maintenance therapy in virologically suppressed HIV-1 infected adults: QDISS open-label trial
Raltegravir 1200 mg once daily as maintenance therapy in virologically suppressed HIV-1 infected adults: QDISS open-label trial Open
View article: Household transmission of SARS-CoV-2 infection in the Paris/Ile-de-France area
Household transmission of SARS-CoV-2 infection in the Paris/Ile-de-France area Open
View article: Kinetics of Archived M184V Mutation in Treatment-Experienced Virally Suppressed HIV-Infected Patients
Kinetics of Archived M184V Mutation in Treatment-Experienced Virally Suppressed HIV-Infected Patients Open
Background We aimed to assess the kinetics of drug-resistant viral variants (DRVs) harboring the M184V mutation in proviral DNA of long-term virally suppressed patients, and factors associated with DRV persistence. Methods Human immunodefi…
View article: Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV
Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV Open
Background Switching from boosted PIs to dolutegravir in people living with HIV (PLWH) with high cardiovascular risk improved plasma lipids at 48 weeks in the NEAT022 trial. Whether this strategy may have an impact on cardiovascular biomar…
View article: Poppers, by Inducing HHV-8 Virion Production, Can Act as a Promoter for HHV-8 Transmission in Men Who Have Sex With Men
Poppers, by Inducing HHV-8 Virion Production, Can Act as a Promoter for HHV-8 Transmission in Men Who Have Sex With Men Open
Environmental factors were reported to increase the risk of human herpesvirus 8 (HHV-8) transmission. In a population of men who have sex with men (MSM), we found evidence that chemsex was associated with human herpesvirus 8 seropositivity…
View article: Intermittent two-drug antiretroviral therapies maintain long-term viral suppression in real life in highly experienced HIV-infected patients
Intermittent two-drug antiretroviral therapies maintain long-term viral suppression in real life in highly experienced HIV-infected patients Open
Objectives To assess in real life whether two-drug regimens (2-DRs) given 4–5 days a week in virally suppressed patients can maintain viral suppression over 48 and 96 weeks. Methods This observational single-centre study enrolled all patie…
View article: Immediate Versus Deferred Switching From a Boosted Protease Inhibitor–based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study
Immediate Versus Deferred Switching From a Boosted Protease Inhibitor–based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study Open
NCT02098837 and EudraCT: 2013-003704-39.
View article: Four-days-a-week antiretroviral maintenance therapy in virologically controlled HIV-1-infected adults: the ANRS 162-4D trial
Four-days-a-week antiretroviral maintenance therapy in virologically controlled HIV-1-infected adults: the ANRS 162-4D trial Open
Antiretroviral maintenance therapy 4 days a week was effective for 48 weeks in 96% of patients, leading to potential reduction of long-term toxicities, high adherence to the antiretroviral regimen and drug cost saving.
View article: Virological factors associated with outcome of dual maraviroc/raltegravir therapy (ANRS-157 trial)
Virological factors associated with outcome of dual maraviroc/raltegravir therapy (ANRS-157 trial) Open
Maraviroc plus raltegravir failed to maintain virological suppression in virologically suppressed HIV-1-infected patients. However, neither minority viral variants nor ultrasensitive viraemia was found to be a predictive factor of VF or vi…